Product
Mirvetuximab Soravtansine
Aliases
IMGN853, M9346A-sulfo-SPDB-DM4, MIRV
Name
Mirvetuximab soravtansine
Target
FRα
FDA Approved
No
Ema approved
Status
0
7 clinical trials
3 abstracts
21 indications
Indication
Recurrent Epithelial OvarianIndication
Fallopian or Peritoneal CarcinomaIndication
Ovarian CancerIndication
Folate Receptor-Alpha PositiveIndication
Peritoneal CancerIndication
Fallopian tube cancerIndication
Breast CancerIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Recurrent Uterine Corpus CarcinomaIndication
Triple-Negative Breast CarcinomaIndication
fallopian tubeIndication
Primary Peritoneal CancerIndication
BRCA1 Gene MutationIndication
BRCA2Indication
Folate-Receptor-Alpha-PositiveIndication
Uterine Serous CarcinomaIndication
Uterine CarcinosarcomaIndication
Platinum-Resistant Ovarian CancerIndication
Endometrial CancerClinical trial
A Randomized Phase II Trial of Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Eligible for Platinum-based Chemotherapy. Supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionStatus: Not yet recruiting, Estimated PCD: 2026-05-26
Clinical trial
A Single-arm, Phase III Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer With High Expression of Folate Receptor-αStatus: Recruiting, Estimated PCD: 2023-04-30
Abstract
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Org: University of Milan-Bicocca, University of California Los Angeles Medical Center, European Institute of Oncology IRCCS, University of Chicago, ImmunoGen,
Clinical trial
A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)Status: Completed, Estimated PCD: 2024-02-09
Clinical trial
Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α PositiveStatus: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2022-06-24
Clinical trial
A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube CancerStatus: Recruiting, Estimated PCD: 2026-04-15